What is an endoteline receptor antagonist?
The endothelin receptor antagonist blocks access to endothelin receptor sites on smooth muscles and organs. Endothelin-1 is one of the three peptides of amino acid endothelin and has two subtypes that cooperate on blood pressure regulation. Scientists have developed an endothelin receptor antagonist that cancels the effects of these two subtypes and ensure vascular relaxation. The possibility of developing liver damage when using drugs requires that patients who use them are carefully monitored. ET-A binds to endothelin-A receptor sites, which are located at the ends of smooth muscles, causing vasoconstriction and at the same time promoting cellular reproduction. The substance also combines with a protein known as GQ, which initiates chemical processes that triggers intracellular sarcoplasmic reticulum to release calcium. Increased calcium levels also cause vasoconstriction, vasospasm and increased contractility and heart rate. Scientists also indicate that peptide contributes to congestive heartsThe pulmonary artery (PAH) failure and hypertension. Studies suggest that under normal conditions both subtypes maintain adequate circulation by performing alternating tasks as needed. Scientists believe that et-A holds the key to pathology behind high blood pressure, commonly referred to as hypertension. Scientists now believe that at some point the balance between ET-A and et-B is scary, causing the dominant hypertensive effects of et-a.
pharmaceutical scientists have developed selective (Ambisentan) antagonist endotelin of the receptor and non -selective (bosentan) en enléky antagonists of the receptor of Dothelin. Doctors can either prescribe medicines as one of the medical treatments of PAH. Ambrisentan inhibits mainly access to ET-A receptor sites, while Bosentan inhibits access to places A and B. by blocking the receptor sites both drugs prevent chemical reactions that contribute to hypertension, ensuring vascular muscle relaxation and lowering blood pressureku.
Studies suggest that individuals taking either drug antagonists have an increased risk of damage or liver failure. Before receiving the prescription for drugs, patients underwent liver enzyme testing, which determines the basic function of the liver. After the patient initiates a prescription, his hepatic function is tested monthly. If testing detects elevated levels of enzymes of liver deflection, drugs may end. Patients who experience loss of appetite, nausea, jaundice and right side, accompanied by a dark -tent with clay urine and light urine and light should consult with a doctor.
Endothelin receptor antagonist drugs are also not recommended for pregnant women due to the risk of congenital defects. Often reported side effects associated with drugs include headaches, flushing of the skin and swelling of the legs and ankles caused by fluid retention. Patients may also experience anemia, reduced sperm number and respiratory infections.